Order Article Reprints

Chen HX, Tsai L-H, Chang C-H, Wu H-C, Lin C-C, Lin C-H, Yeh C-C, Yang C-R, Lien C-S, Chang Y-H, et al. Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study. Cancers. 2023; 15(13):3516. https://doi.org/10.3390/cancers15133516

Chen, Hao Xiang, Li-Hsien Tsai, Chao-Hsiang Chang, Hsi-Chin Wu, Ching-Chan Lin, Che-Hung Lin, Chin-Chung Yeh, Chi-Rei Yang, Chi-Shun Lien, Yi-Huei Chang, and et al. 2023. "Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study" Cancers 15, no. 13: 3516. https://doi.org/10.3390/cancers15133516

Chen, H. X., Tsai, L.-H., Chang, C.-H., Wu, H.-C., Lin, C.-C., Lin, C.-H., Yeh, C.-C., Yang, C.-R., Lien, C.-S., Chang, Y.-H., Liang, J.-A., Chen, G.-H., Hsiao, P.-J., Hsieh, P.-F., & Huang, C.-P. (2023). Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study. Cancers, 15(13), 3516. https://doi.org/10.3390/cancers15133516